Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03598244 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03598244 · ClinicalTrials.gov record · last posted 2026-07-30

Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Name: Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors — clinical trial record (NCT03598244)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorNational Cancer Institute (NCI)

Started2018-11-27

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This phase I trial studies the side effects and best dose of savolitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Protocol amendment history 2 changes detected by DataLookout

2026-07-31

Primary completion pushed: 2025-04-14 → 2026-04-22

2026-07-31

Completion pushed: 2026-09-12 → 2027-05-27

Trial Details

NCT Number	NCT03598244
Lead Sponsor	National Cancer Institute (NCI)
Conditions	Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Enrollment	41 participants
Start Date	2018-11-27
Primary Completion	2026-04-22 (estimated)
Study Completion	2027-05-27 (estimated)
Updated on ClinicalTrials.gov	2026-07-30